Development of a cell-targeted liposome formulation for small cell lung cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Tipo de documento: | Trabalho de conclusão de curso |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/183371 |
Resumo: | Lung cancer is one of the most common cancers with small cell lung cancer (SCLC) representing 18% of the total lung cancer diagnoses. Conventional treatments include the administration of high dosages of cisplatin, but as most anti-cancer agents, this drug is not targeted which causes toxicity and undesirable severe side-effects which limit its clinical application. Liposome-based formulations have been recently exploited for improving the delivery and therapeutic effect of cisplatin (Lipoplatin®). In this study, we sought to generate a targeted liposomal formulation. The gastrin releasing peptide (GRP) receptor is over-expressed on many cancer cells including SCLC. A conventional liposomal cisplatin formulation was modified by adding a GRP receptor agonist to a pegylated lipid which was then inserted into pre-formed liposomes. However, the biological activity of peptide-modified liposomal cisplatin was comparable to the control liposomes when tested on GRP receptor positive SCLC cells (NCI-H345), and GRP receptor negative control cells (A549), using the MTS assay. ICP-AES analysis of cisplatin encapsulation efficiency showed encapsulation to be decreased in the targeted formulation. Fluorescence liposomes were also prepared to evaluate the uptake of the cells, using carboxyfluorescein as fluorescence agent. Results shows higher uptake by target- liposomes. |
id |
UFRGS-2_0dcccf4d797259c06743ed63e3246572 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/183371 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Ferreira, Pâmela Cristina LukasewiczFroehlich, Pedro Eduardo2018-10-16T02:43:05Z2014http://hdl.handle.net/10183/183371000937528Lung cancer is one of the most common cancers with small cell lung cancer (SCLC) representing 18% of the total lung cancer diagnoses. Conventional treatments include the administration of high dosages of cisplatin, but as most anti-cancer agents, this drug is not targeted which causes toxicity and undesirable severe side-effects which limit its clinical application. Liposome-based formulations have been recently exploited for improving the delivery and therapeutic effect of cisplatin (Lipoplatin®). In this study, we sought to generate a targeted liposomal formulation. The gastrin releasing peptide (GRP) receptor is over-expressed on many cancer cells including SCLC. A conventional liposomal cisplatin formulation was modified by adding a GRP receptor agonist to a pegylated lipid which was then inserted into pre-formed liposomes. However, the biological activity of peptide-modified liposomal cisplatin was comparable to the control liposomes when tested on GRP receptor positive SCLC cells (NCI-H345), and GRP receptor negative control cells (A549), using the MTS assay. ICP-AES analysis of cisplatin encapsulation efficiency showed encapsulation to be decreased in the targeted formulation. Fluorescence liposomes were also prepared to evaluate the uptake of the cells, using carboxyfluorescein as fluorescence agent. Results shows higher uptake by target- liposomes.application/pdfengNeoplasias pulmonaresLipossomosSmall-lung cancerBombesinLiposomeCisplatinFluorescenceDevelopment of a cell-targeted liposome formulation for small cell lung cancerinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesisUniversidade Federal do Rio Grande do SulFaculdade de FarmáciaPorto Alegre, BR-RS2014Farmáciagraduaçãoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000937528.pdfTexto completo (inglês)application/pdf1160651http://www.lume.ufrgs.br/bitstream/10183/183371/1/000937528.pdfbf6d02baf020cade1d33ff21a10af4a4MD51TEXT000937528.pdf.txt000937528.pdf.txtExtracted Texttext/plain68594http://www.lume.ufrgs.br/bitstream/10183/183371/2/000937528.pdf.txt898ee1a6d68443d34c1889a11caeb16eMD52THUMBNAIL000937528.pdf.jpg000937528.pdf.jpgGenerated Thumbnailimage/jpeg1330http://www.lume.ufrgs.br/bitstream/10183/183371/3/000937528.pdf.jpgb0dff7df2bc4e76349369301fead8784MD5310183/1833712018-10-17 02:37:29.745366oai:www.lume.ufrgs.br:10183/183371Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2018-10-17T05:37:29Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Development of a cell-targeted liposome formulation for small cell lung cancer |
title |
Development of a cell-targeted liposome formulation for small cell lung cancer |
spellingShingle |
Development of a cell-targeted liposome formulation for small cell lung cancer Ferreira, Pâmela Cristina Lukasewicz Neoplasias pulmonares Lipossomos Small-lung cancer Bombesin Liposome Cisplatin Fluorescence |
title_short |
Development of a cell-targeted liposome formulation for small cell lung cancer |
title_full |
Development of a cell-targeted liposome formulation for small cell lung cancer |
title_fullStr |
Development of a cell-targeted liposome formulation for small cell lung cancer |
title_full_unstemmed |
Development of a cell-targeted liposome formulation for small cell lung cancer |
title_sort |
Development of a cell-targeted liposome formulation for small cell lung cancer |
author |
Ferreira, Pâmela Cristina Lukasewicz |
author_facet |
Ferreira, Pâmela Cristina Lukasewicz |
author_role |
author |
dc.contributor.author.fl_str_mv |
Ferreira, Pâmela Cristina Lukasewicz |
dc.contributor.advisor1.fl_str_mv |
Froehlich, Pedro Eduardo |
contributor_str_mv |
Froehlich, Pedro Eduardo |
dc.subject.por.fl_str_mv |
Neoplasias pulmonares Lipossomos |
topic |
Neoplasias pulmonares Lipossomos Small-lung cancer Bombesin Liposome Cisplatin Fluorescence |
dc.subject.eng.fl_str_mv |
Small-lung cancer Bombesin Liposome Cisplatin Fluorescence |
description |
Lung cancer is one of the most common cancers with small cell lung cancer (SCLC) representing 18% of the total lung cancer diagnoses. Conventional treatments include the administration of high dosages of cisplatin, but as most anti-cancer agents, this drug is not targeted which causes toxicity and undesirable severe side-effects which limit its clinical application. Liposome-based formulations have been recently exploited for improving the delivery and therapeutic effect of cisplatin (Lipoplatin®). In this study, we sought to generate a targeted liposomal formulation. The gastrin releasing peptide (GRP) receptor is over-expressed on many cancer cells including SCLC. A conventional liposomal cisplatin formulation was modified by adding a GRP receptor agonist to a pegylated lipid which was then inserted into pre-formed liposomes. However, the biological activity of peptide-modified liposomal cisplatin was comparable to the control liposomes when tested on GRP receptor positive SCLC cells (NCI-H345), and GRP receptor negative control cells (A549), using the MTS assay. ICP-AES analysis of cisplatin encapsulation efficiency showed encapsulation to be decreased in the targeted formulation. Fluorescence liposomes were also prepared to evaluate the uptake of the cells, using carboxyfluorescein as fluorescence agent. Results shows higher uptake by target- liposomes. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014 |
dc.date.accessioned.fl_str_mv |
2018-10-16T02:43:05Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
format |
bachelorThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/183371 |
dc.identifier.nrb.pt_BR.fl_str_mv |
000937528 |
url |
http://hdl.handle.net/10183/183371 |
identifier_str_mv |
000937528 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/183371/1/000937528.pdf http://www.lume.ufrgs.br/bitstream/10183/183371/2/000937528.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/183371/3/000937528.pdf.jpg |
bitstream.checksum.fl_str_mv |
bf6d02baf020cade1d33ff21a10af4a4 898ee1a6d68443d34c1889a11caeb16e b0dff7df2bc4e76349369301fead8784 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224559533228032 |